Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.

The couple’s decades-long battle with cancer highlights the lifesaving power of early detection and self-advocacy.

Vincent Gakuhi, a cancer survivor who scored an A in KCSE despite writing his exam in pain, during an interview at their home in Ruaka, Nairobi. On the morning the first Kenya Certificate of Secondary ...

The Shining Star Awards ceremony took place at Tower Bridge, London in November 2025. Northern Ireland nominees recognised in ...

Agenus Inc. ( Nasdaq: AGEN ), a leader in immuno-oncology innovation, today announced that France’s National Agency for ...

Staff at HCA HealthONE Swedish organized a free wedding for a couple after the bride was diagnosed with a rare sarcoma.

For months, Tasmanian Aidyn Clements ignored the fatigue she put down to motherhood - until one ordinary evening revealed a ...

A family’s bitter loss three years ago when 16-year-old Eoghan Homan did not survive his medical battle has been carried ...

Kelly Mullooly, a 19-year-old studying at the University of New Haven, was diagnosed with a rare form of bone cancer called osteosarcoma at age 18, after persistent knee pain. She underwent ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved treatments, prompting the San Diego biotech to plot a submission to the FDA ...

Small blue round cells of Ewing Sarcoma. Nat Pernick, CC BY 3.0, via Wikimedia Commons Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. A ...

BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and ...